Immunome to Present at the Stifel 2023 Healthcare Conference

SEATTLE & EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Immunome, Inc.

Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.

For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231110745339/en/

Investor Contact
Corleen Roche
Chief Financial Officer
[email protected]

Media Contact
Andrew W. Mielach
LifeSci Communications
[email protected]

Source: Immunome, Inc.

You May Also Be Interested In

• Cinemo, Dolby, and SmashLabs Bring In-Car Immersive Gaming Experiences to the Next Level
• AXIS-Y Launches Triple PDRN Barrier Boost Serum, Its Most Advanced Recovery Formula Yet
• Ibogaine By David Dardashti Releases Unprecedented Clinical Footage of Full Treatment Protocol Amid Federal Push for Psychedelic Therapy